Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia
Status:
Not yet recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to observe the clinical efficacy and adverse reactions of rhTPO
in the treatment of pregnancy-induced thrombocytopenia.
Phase:
Phase 3
Details
Lead Sponsor:
Shandong University
Collaborators:
First Affiliated Hospital of Chongqing Medical University Linyi People's Hospital Peking University People's Hospital Shandong Provincial Hospital The Affiliated Hospital of Qingdao University Zhongshan Bo Ai Hospital